Excellent commentary from MT here.
I also struggle with this ethical issue. Patients on STRIKE who receive the placebo will be on the Standard of Care treatment, as such, in theory, they are no worse off than they would otherwise have been. But in the case of ALS/MND, there IS NO standard of care that derives a benefit for the patient. Patients in the trial on the placebo will be substantially worse off - on the ALSFRS-R score possibly around .5 pt worse per month - for about 10 months in Australia. Those 5 points may see the patient in a wheelchair, or incubated, a year or two earlier than would otherwise be the case.
Maybe Berry Consultants have the answer.
Excellent commentary from MT here.I also struggle with this...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.020(8.89%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.5¢ | $331.9K | 1.617M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 440882 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 12736 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |